Second Sight Medical Products Inc. (NASDAQ:EYES) shares saw unusually-high trading volume on Monday . Approximately 1,162,144 shares traded hands during mid-day trading, an increase of 80% from the previous session’s volume of 644,668 shares.The stock last traded at $4.24 and had previously closed at $4.13.

Separately, Zacks Investment Research lowered shares of Second Sight Medical Products from a “hold” rating to a “sell” rating in a report on Monday, April 4th.

The company’s market capitalization is $152.80 million. The firm’s 50 day moving average price is $3.86 and its 200 day moving average price is $4.47.

Second Sight Medical Products (NASDAQ:EYES) last issued its quarterly earnings data on Thursday, April 28th. The medical device company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.03. The firm had revenue of $1.05 million for the quarter, compared to analysts’ expectations of $1.38 million. During the same period in the prior year, the firm posted ($0.12) EPS. Second Sight Medical Products’s revenue was down 38.2% on a year-over-year basis. On average, equities research analysts expect that Second Sight Medical Products Inc. will post ($0.65) EPS for the current year.

In other Second Sight Medical Products news, Chairman Robert J. Greenberg sold 8,571 shares of the business’s stock in a transaction that occurred on Thursday, June 2nd. The shares were sold at an average price of $4.10, for a total value of $35,141.10. Following the completion of the transaction, the chairman now owns 172,911 shares of the company’s stock, valued at approximately $708,935.10. The transaction was disclosed in a filing with the SEC, which is available through this link.

Second Sight Medical Products, Inc is a medical device company that develops, manufactures and markets implantable visual prosthetics to restore some functional vision to blind patients. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.